Tuesday, February 25, 2020 6:08:36 PM
I posted that. Tim Currently owns 32% of the company and is CEO so controls 32% more. He has 64% voting rights (as shown in the voting numbers for the R/S).
The COMPANY, TW and a few officers own about 10 million shares. There are 17.5 outstanding. I would like to buy as many of those 7.5 while they are still worth pennies...
$2,000 is 1% of the company at todays PPS... gobble them up before a buyout or force a lock up of shares.
With conversions, i think the final O/S is going to be 22-25 million. So dont freak out when there is more dilution becuase it clearly shows more.
25 Million O/S and Selling the company for 50-100 million, is still 2-4$ PPS... Thats the new goal.
THIS IS WAY UNDERVALUED... Tim would not have R/S to just let it sit, something is going to change in the next couple months. It is my understanding fins are due by the end of the month and then the next set is in May (for March Q) and we can see their progress.
The COMPANY, TW and a few officers own about 10 million shares. There are 17.5 outstanding. I would like to buy as many of those 7.5 while they are still worth pennies...
$2,000 is 1% of the company at todays PPS... gobble them up before a buyout or force a lock up of shares.
With conversions, i think the final O/S is going to be 22-25 million. So dont freak out when there is more dilution becuase it clearly shows more.
25 Million O/S and Selling the company for 50-100 million, is still 2-4$ PPS... Thats the new goal.
THIS IS WAY UNDERVALUED... Tim would not have R/S to just let it sit, something is going to change in the next couple months. It is my understanding fins are due by the end of the month and then the next set is in May (for March Q) and we can see their progress.
Recent CELZ News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/20/2026 08:45:28 PM
- Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline • GlobeNewswire Inc. • 02/10/2026 02:00:00 PM
- Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain • GlobeNewswire Inc. • 01/13/2026 02:15:00 PM
- Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative • GlobeNewswire Inc. • 01/06/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/31/2025 09:05:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 09:01:58 PM
- Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point • GlobeNewswire Inc. • 12/17/2025 02:15:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/16/2025 09:05:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/15/2025 05:15:26 AM
- Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 • GlobeNewswire Inc. • 12/02/2025 02:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/21/2025 09:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 11:12:58 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2025 09:46:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:42 PM
- Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits • GlobeNewswire Inc. • 10/30/2025 01:15:00 PM
- Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds • GlobeNewswire Inc. • 10/29/2025 01:00:00 PM
- Creative Medical Technology Holdings Issues Letter to Shareholders • GlobeNewswire Inc. • 10/27/2025 12:15:00 PM
- Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs • GlobeNewswire Inc. • 10/07/2025 01:15:00 PM
- Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain • GlobeNewswire Inc. • 08/13/2025 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2025 08:45:55 PM
- Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells • GlobeNewswire Inc. • 07/17/2025 01:15:00 PM
